[1] 乔勤, 顾波, 马骏. 我国与全球终末期肾脏病的流行现状[J].中国血液净化, 2014, 13(10):729-732. [2] 许雪强, 陈竹筠, 邬步云,等. 终末期肾病患者骨质疏松的危险因素分析[J].肾脏病与透析肾移植杂志, 2016, 25(6):513-518. [3] Viaene L, Behets G J, Heye S,et al.Inflammation and the bone-vascular axis in end-stage renal disease[J].Osteoporos Int,2016, 27(2):489-497. [4] 周俊, 唐昊, 李咏雪. 各类骨密度检测设备的工作原理及实现技术比较分析[J].中国医疗设备, 2016, 31(6):81-83. [5] 张瑜凌, 王梦婧, 张敏敏,等. 维持性血液透析患者骨质疏松的危险因素分析[J].中华肾脏病杂志, 2016, 32(4):259-263. [6] 杨洁,康建国,吕艳伟,等.各期慢性肾脏病患者腰椎定量CT骨密度与骨代谢指标的关系[J].中国老年学杂志,2016,36(14):3518-3522. [7] Doukky R,Fughhi I,Campagnoli T,et al.The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease[J].J Nucl Cardiol,2017,24(1):112-118. [8] 鲁志科,孙榕.老年骨质疏松合并高血压患者骨密度及骨代谢标志物的临床研究[J].医学临床研究,2017,34(11):2200-2202. [9] Aleksova J,Kurniawan S,Elder GJ.The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease[J].Osteoporos Int,2018,29(6):1447-1455. [10] Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease[J].Intern Med,2017,56(24):3271-3276. [11] 张小红,陈财铭,万建新.非透析慢性肾脏病患者骨量异常与血管钙化的危险因素[J].中华肾脏病杂志,2017,33(2):100-105. [12] Wilson LM,Rebholz CM,Jirru E,et al.Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis[J].Ann Intern Med,2017,166(9):649-658.
2018, Vol. 35 
